Uncover key drivers, emerging technologies, and competitive movements shaping the sodium glucose cotransporter 2 (sglt2) inhibitors market from 2026–2035 with trusted insights from The Business Research Company

Starting from its 2026 valuation, what market size is the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market expected to reach by 2030?

The sodium glucose cotransporter 2 (sglt2) inhibitors market size has seen significant growth in recent years. It is anticipated to increase from $10.96 billion in 2025 to $11.87 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.3%. The expansion observed in prior periods is attributable to factors such as a rise in type 2 diabetes cases, unfulfilled glycemic control requirements, positive clinical trial results, increased physician knowledge, and various regulatory approvals.

The market for sodium glucose cotransporter 2 (sglt2) inhibitors anticipates substantial expansion in the coming years. It is projected to reach $16.35 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.3%. Key factors contributing to this growth during the forecast period include the acknowledgment of cardio-renal benefits, an increasing aging diabetic demographic, broader reimbursement coverage, the introduction of new drugs, and greater penetration into emerging markets. Significant trends expected over the forecast period encompass the extended application of these inhibitors beyond diabetes, a rise in the adoption of combination therapies, an expansion in their use for heart failure indications, enhanced safety profiles, and their broader incorporation into clinical guidelines.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18473&type=smp

What Drivers Are Driving Adoption Within The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?

The anticipated expansion of the sodium glucose cotransporter 2 (SGLT2) inhibitor market is closely linked to the rising incidence of diabetes. Diabetes encompasses a set of metabolic conditions marked by elevated blood glucose levels, stemming from deficiencies in either insulin secretion, its action, or a combination of both. The increase in diabetes diagnoses can be attributed to factors such as urbanization, stress, environmental contaminants, and limited access to healthcare. In diabetes management, Sodium glucose cotransporter 2 (SGLT2) inhibitors work by reducing blood glucose through blocking glucose reabsorption in the kidneys, thereby promoting its elimination via urine. These inhibitors also provide advantages for cardiovascular and kidney health, establishing them as a crucial choice for addressing diabetes and its associated complications. For instance, in March 2025, the Office for Health Improvement and Disparities (OHID), a UK-Based English government organization, reported that the prevalence of type 2 diabetes among adults aged 17 and over in England, as documented by GPs, reached 7.0% in March 2024, an increase from 6.8% in March 2023. Consequently, the expanding occurrence of diabetes is fueling the growth of the sodium glucose cotransporter 2 (SGLT2) inhibitor market.

How Is The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Organized Into Various Segments?

The sodium glucose cotransporter 2 (sglt2) inhibitors market covered in this report is segmented –

1) By Type: Invokana, Jardiance, Farxiga Or Forxiga, Suglat

2) By Route Of Administration: Oral Route, Other Route Of Administration

3) By End User: Hospitals, Homecare Settings, Clinics

Subsegments:

1) By Invokana: Generic Invokana (Canagliflozin), Branded Invokana

2) By Jardiance: Generic Jardiance (Empagliflozin), Branded Jardiance

3) By Farxiga Or Forxiga: Generic Farxiga (Dapagliflozin), Branded Farxiga

4) By Suglat: Suglat (Sotagliflozin) For Diabetes, Suglat (Sotagliflozin) For Heart Failure

What Industry Trends Are Transforming The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?

Leading firms within the sodium glucose cotransporter 2 (SGLT2) inhibitor market are concentrating on creating dual inhibitor therapeutic solutions aimed at enhancing patient results and regulating blood sugar. These dual inhibitor solutions denote therapies designed to concurrently target two distinct sodium-glucose cotransporters (SGLT1 and SGLT2), thereby boosting their effectiveness in treating ailments like heart failure and diabetes. An example of this is the approval in May 2023 by the Food and Drug Administration (FDA) of sotagliflozin, a heart failure treatment, for Lexicon Pharmaceuticals Inc., a US-based biopharmaceutical company. This pioneering dual inhibitor of sodium-glucose cotransporters 1 and 2 is formulated as a once-daily tablet, intended to decrease cardiovascular mortality, hospitalizations due to heart failure, and urgent visits for heart failure in adult patients suffering from heart failure, type 2 diabetes, chronic kidney disease, and additional cardiovascular risk factors. Its advantages encompass diminished renal glucose and sodium reabsorption, contributing to reductions in preload and afterload, alongside a decrease in sympathetic activity.

Who Are The Primary Competitors In The Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?

Major companies operating in the sodium glucose cotransporter 2 (sglt2) inhibitors market are Johnson & Johnson Inc., Merck & Co Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Astellas Pharma Inc, Sun Pharmaceutical Industries Ltd, Sumitomo Dainippon Pharma Co Ltd, Taisho Pharmaceutical Holdings Co Ltd, Lupin Limited, Glenmark Pharmaceuticals, Torrent Pharmaceuticals Ltd, Mankind Pharma Ltd, Kissei Pharmaceutical Co Ltd, Kotobuki Pharmaceutical Co Ltd, Lexicon Pharmaceuticals Inc, Novartis AG, Takeda Pharmaceutical Company Limited, Hanmi Pharmaceutical Co Ltd, Chong Kun Dang Pharmaceutical Corp, Mitsubishi Tanabe Pharma Corporation

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/sodium-glucose-cotransporter-2-sglt2-inhibitors-global-market-report

Which Global Regions Are Shaping The Competitive Landscape Of The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?

North America was the largest region in the sodium glucose cotransporter 2 (SGLT2) inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sodium glucose cotransporter 2 (sglt2) inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=18473&type=smp

Browse Through More Reports Similar to the Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market 2026, By The Business Research Company

Kinase Inhibitors Market Report 2026

https://www.thebusinessresearchcompany.com/report/kinase-inhibitors-global-market-report

Antidiabetics Market Report 2026

https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report

Mtor Inhibitors Market Report 2026

https://www.thebusinessresearchcompany.com/report/mtor-inhibitors-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.